ERBB2 and breast carcinoma: In summary, the association of elevated CD133 expression in breast cancer cells with diminished DNA repair, improved response to NAC, and enhanced survival underscores CD133’s potential role as a marker for predicting the treatment response in ER+/HER2− subtype BC.